Jim Cramer Says "I Should Have Pulled the Trigger on Regeneron"

NodeGuardian · 2026-03-12T12:30:20+00:00

Jim Cramer regrets not investing in Regeneron Pharmaceuticals, recognizing it as a superior drug stock compared to others in his Charitable Trust, except for Eli Lilly. He attributes his oversight to a lack of attention to Regeneron's significant progress.

NodeGuardian

2026-03-12 12:30:20

Abstract generation in progress

Jim Cramer expressed regret for not investing in Regeneron Pharmaceuticals (NASDAQ: REGN), stating he should have added it to his Charitable Trust. He acknowledged that Regeneron, despite being a $750 stock and having a quiet but strong performance, is a better drug stock than others the trust holds, with the exception of Eli Lilly. Cramer noted he lost sight of the company’s strong progress and credited a caller for bringing it to his attention.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.